Literature DB >> 10233722

The lifespan of major histocompatibility complex class I/peptide complexes determines the efficiency of cytotoxic T-lymphocyte responses.

F Micheletti1, M Bazzaro, A Canella, M Marastoni, S Traniello, R Gavioli.   

Abstract

Major histocompatibility complex (MHC)/peptide association and stability are determined by specific amino acid interactions between peptide antigens and the MHC groove, and are regarded as a critical feature in ensuring efficient monitoring by T cells. In this investigation we examined the relationship between MHC/peptide stability and the immunostimulatory capacity of MHC/peptide complexes. For this purpose we compared synthetic peptide analogues derived from the immunodominant HLA-A11-presented IVTDFSVIK (IVT) epitope, for their capacity to reactivate IVT-specific memory cytotoxic T-lymphocyte (CTL) responses. The analogues differentiated from the wild-type epitope by single amino acid substitution at position 2. All peptides showed similar affinity for HLA-A11 molecules and were recognized by IVT-specific CTL clones, but induced HLA-A11 complexes at the cell surface with different lifespan. This model offered the possibility of comparing the capacity of an immunogenic epitope to stimulate a unique population of T-cell precursors depending on the lifespan of its presentation at the cell surface. We demonstrated that stable HLA-A11/peptide complexes efficiently stimulate IVT-specific CTL responses, while HLA-A11/peptide complexes with short lifespan do not. The precise identification of the role of amino acid residues in the formation of stable MHC/peptide complexes may be relevant for the design of wild-type-derived epitopes with high immunogenicity. These analogues may have important applications in the immunotherapy of infectious diseases and immunogenic tumours.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233722      PMCID: PMC2326763          DOI: 10.1046/j.1365-2567.1999.00707.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

1.  Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.

Authors:  M G Masucci; Q J Zhang; R Gavioli; P O De Campos-Lima; R J Murray; J Brooks; H Griffin; H Ploegh; A B Rickinson
Journal:  Int Immunol       Date:  1992-11       Impact factor: 4.823

2.  Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.

Authors:  R Gavioli; P O De Campos-Lima; M G Kurilla; E Kieff; G Klein; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

3.  Association of class I major histocompatibility heavy and light chains induced by viral peptides.

Authors:  A Townsend; C Ohlén; J Bastin; H G Ljunggren; L Foster; K Kärre
Journal:  Nature       Date:  1989-08-10       Impact factor: 49.962

4.  Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution.

Authors:  M A Saper; P J Bjorkman; D C Wiley
Journal:  J Mol Biol       Date:  1991-05-20       Impact factor: 5.469

5.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.

Authors:  K Falk; O Rötzschke; S Stevanović; G Jung; H G Rammensee
Journal:  Nature       Date:  1991-05-23       Impact factor: 49.962

6.  Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.

Authors:  R Gavioli; M G Kurilla; P O de Campos-Lima; L E Wallace; R Dolcetti; R J Murray; A B Rickinson; M G Masucci
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

7.  Specificity pockets for the side chains of peptide antigens in HLA-Aw68.

Authors:  T P Garrett; M A Saper; P J Bjorkman; J L Strominger; D C Wiley
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

8.  An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins.

Authors:  Q J Zhang; R Gavioli; G Klein; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

9.  The effect of anchor residue modifications on the stability of major histocompatibility complex class I-peptide interactions.

Authors:  J J Neefjes; J Dierx; H L Ploegh
Journal:  Eur J Immunol       Date:  1993-04       Impact factor: 5.532

10.  HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population.

Authors:  P O de Campos-Lima; R Gavioli; Q J Zhang; L E Wallace; R Dolcetti; M Rowe; A B Rickinson; M G Masucci
Journal:  Science       Date:  1993-04-02       Impact factor: 47.728

View more
  9 in total

1.  Function-related regulation of the stability of MHC proteins.

Authors:  A Simon; Z s Dosztányi; E Rajnavölgyi; I Simon
Journal:  Biophys J       Date:  2000-11       Impact factor: 4.033

2.  Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance.

Authors:  Ian A York; Michael A Brehm; Sophia Zendzian; Charles F Towne; Kenneth L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

3.  Impaired dendritic cell function in aging leads to defective antitumor immunity.

Authors:  Annabelle Grolleau-Julius; Erin K Harning; Lisa M Abernathy; Raymond L Yung
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

4.  Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope.

Authors:  Diego Marescotti; Federica Destro; Anna Baldisserotto; Mauro Marastoni; Giuseppe Coppotelli; Maria Masucci; Riccardo Gavioli
Journal:  Immunology       Date:  2009-11-16       Impact factor: 7.397

5.  A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.

Authors:  Jeffrey S Weber; Nicholas J Vogelzang; Marc S Ernstoff; Oscar B Goodman; Lee D Cranmer; John L Marshall; Sabrina Miles; Dar Rosario; David C Diamond; Zhiyong Qiu; Mihail Obrocea; Adrian Bot
Journal:  J Immunother       Date:  2011-09       Impact factor: 4.456

6.  Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8.

Authors:  Fabiola Micheletti; Paolo Monini; Cinzia Fortini; Paola Rimessi; Martina Bazzaro; Massimo Andreoni; Massimo Giuliani; Serena Traniello; Barbara Ensoli; Riccardo Gavioli
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

7.  Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes.

Authors:  P Savage; P Cowburn; A Clayton; S Man; A McMichael; N Lemoine; A Epenetos; G Ogg
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

8.  Targeting the coding sequence: opposing roles in regulating classical and non-classical MHC class I molecules by miR-16 and miR-744.

Authors:  Michael Friedrich; Christoforos K Vaxevanis; Katharina Biehl; Anja Mueller; Barbara Seliger
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

Review 9.  Antigen processing and presentation in cancer immunotherapy.

Authors:  Maxwell Y Lee; Jun W Jeon; Cem Sievers; Clint T Allen
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.